^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | dacarbazine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
01/19/2021
Excerpt:
Recommendations: Dacarbazine/temozolomide–based ChT as first line, and platinum-based ChT as second line, are recommended in advanced LC patients refractory or intolerant to everolimus therapy [IV, C]….Upfront everolimus or dacarbazine/temozolomide–based or oxaliplatin-based ChT is recommended, or in selected subgroup PRRT (based on positive uptake at SRI on all RECIST evaluable targets) in high proliferative atypical carcinoids [V, C].
DOI:
10.1016/j.annonc.2021.01.003
Source:
Excerpt:
Neuroendocrine Tumors of the Gastrointestinal Tract (Well-Differentiated Grade 1/2): Locoregional Advanced Disease and/or Distant Metastases (if progression on octreotide or lanreotide)...Useful in Certain Circumstances...Cytotoxic chemotherapy, if no other options feasible (all category 3): Anticancer agents such as 5-fluorouracil (5-FU), capecitabine, dacarbazine, oxaliplatin, streptozocin, and temozolomide can be used in patients with progressive metastases for whom there are no other treatment options.
